Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 92

1.

Antibody depletion by bortezomib through blocking of antigen presentation.

Park SJ, Cheong HI, Shin JI.

N Engl J Med. 2013 Apr 4;368(14):1364-5. doi: 10.1056/NEJMc1301264. No abstract available.

PMID:
23550684
[PubMed - indexed for MEDLINE]
Free Article
2.

ADAMTS13 antibody depletion by bortezomib in thrombotic thrombocytopenic purpura.

Shortt J, Oh DH, Opat SS.

N Engl J Med. 2013 Jan 3;368(1):90-2. doi: 10.1056/NEJMc1213206. No abstract available.

PMID:
23281998
[PubMed - indexed for MEDLINE]
Free Article
3.

Bortezomib induces clinical remission and reduction of ADAMTS13 inhibitory antibodies in relapsed refractory idiopathic thrombotic thrombocytopenic purpura.

Mazepa MA, Raval JS, Moll S, Ma A, Park YA.

Br J Haematol. 2014 Mar;164(6):900-2. doi: 10.1111/bjh.12696. Epub 2013 Dec 17. No abstract available.

PMID:
24345005
[PubMed - indexed for MEDLINE]
4.

Proteasome inhibition: a new therapeutic option in lupus nephritis?

van der Vlag J, Berden JH.

Nephrol Dial Transplant. 2008 Dec;23(12):3771-2. doi: 10.1093/ndt/gfn536. Epub 2008 Sep 22. Review. No abstract available.

PMID:
18809973
[PubMed - indexed for MEDLINE]
Free Article
5.

Successful treatment of IgM-mediated autoimmune hemolytic anemia with bortezomib.

Carson KR, Beckwith LG, Mehta J.

Blood. 2010 Jan 28;115(4):915. doi: 10.1182/blood-2009-09-242917. No abstract available.

PMID:
20110437
[PubMed - indexed for MEDLINE]
Free Article
6.

Bortezomib for the treatment of de novo HLA antibody-related antibody mediated rejection.

Al Meshari K.

Clin Transpl. 2009:385-6. No abstract available.

PMID:
20524302
[PubMed - indexed for MEDLINE]
7.

Targeting plasma cells with proteasome inhibitors: possible roles in treating myasthenia gravis?

Gomez AM, Willcox N, Molenaar PC, Buurman W, Martinez-Martinez P, De Baets MH, Losen M.

Ann N Y Acad Sci. 2012 Dec;1274:48-59. doi: 10.1111/j.1749-6632.2012.06824.x. Review.

PMID:
23252897
[PubMed - indexed for MEDLINE]
8.

Successful bortezomib-based treatment in POEMS syndrome.

Tang X, Shi X, Sun A, Qiu H, Gu B, Zhou H, Xue S, Liu Y, Ruan C, Wu D.

Eur J Haematol. 2009 Dec 1;83(6):609-10. doi: 10.1111/j.1600-0609.2009.01330.x. Epub 2009 Aug 6. No abstract available.

PMID:
19674063
[PubMed - indexed for MEDLINE]
9.

Use of bortezomib as adjunctive therapy for densensitization in combined heart and kidney transplantation--a case report.

Patel JK, Everly MJ, Kittleson M, Kobashigawa JA.

Clin Transpl. 2009:347-9. No abstract available.

PMID:
20524297
[PubMed - indexed for MEDLINE]
10.

[Recent progress of diagnosis and treatment for immune-mediated hematological diseases. Topics: III. Diagnosis and treatment; 4. Thrombotic thrombocytopenic purpura].

Matsumoto M.

Nihon Naika Gakkai Zasshi. 2014 Jul 10;103(7):1613-21. Japanese. No abstract available.

PMID:
25154256
[PubMed - indexed for MEDLINE]
11.

Efficacy of rituximab and concurrent plasma exchange in the treatment of thrombotic thrombocytopenic purpura.

Hull MJ, Eichbaum QG.

Clin Adv Hematol Oncol. 2006 Mar;4(3):210-4; discussion 217-8. No abstract available.

PMID:
16728930
[PubMed - indexed for MEDLINE]
12.

The state of therapy for removal of alloantibody producing plasma cells in transplantation.

Everly MJ, Terasaki PI.

Semin Immunol. 2012 Apr;24(2):143-7. doi: 10.1016/j.smim.2011.08.014. Epub 2011 Dec 5. Review.

PMID:
22153981
[PubMed - indexed for MEDLINE]
13.

Unraveling the immunologic response in thrombotic thrombocytopenic purpura.

Knöbl P.

J Thromb Haemost. 2006 Nov;4(11):2352-4. Epub 2006 Aug 23. No abstract available.

PMID:
16938122
[PubMed - indexed for MEDLINE]
14.

Proteasome inhibition for antibody-mediated rejection.

Everly JJ, Walsh RC, Alloway RR, Woodle ES.

Curr Opin Organ Transplant. 2009 Dec;14(6):662-6. doi: 10.1097/MOT.0b013e328330f304. Review.

PMID:
19667989
[PubMed - indexed for MEDLINE]
15.

Elimination of post-transplant donor-specific HLA antibodies with bortezomib.

Idica A, Kaneku H, Everly MJ, Trivedi HL, Feroz A, Vanikar AV, Shankar V, Trivedi VB, Modi PR, Khemchandani SI, Dave SD, Terasaki PI.

Clin Transpl. 2008:229-39.

PMID:
19708459
[PubMed - indexed for MEDLINE]
16.

Bortezomib as therapy for mixed humoral and cellular rejection: should it be first line?

Lee I, Constantinescu S, Gillespie A, Swami A, Birkenbach M, Leech S, Silva P, Karachristos A, Daller JA, Sifontis NM.

Clin Transpl. 2009:425-9. No abstract available.

PMID:
20524309
[PubMed - indexed for MEDLINE]
17.

Bortezomib for antibody mediated rejection treatment: experience at the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán in Mexico City.

Leyva S, Marino-Vázquez LA, Reyes-Loaeza JA, Vega O, Uribe-Uribe N, Alberú J, Morales-Buenrostro LE.

Clin Transpl. 2009:369-76.

PMID:
20524300
[PubMed - indexed for MEDLINE]
18.

Bortezomib in multiple myeloma.

Faix JD.

N Engl J Med. 2003 Sep 25;349(13):1287-8; author reply 1287-8. No abstract available.

PMID:
14507954
[PubMed - indexed for MEDLINE]
Free Article
19.

The early marginal zone B cell-initiated T-independent type 2 response resists the proteasome inhibitor bortezomib.

Lang VR, Mielenz D, Neubert K, Böhm C, Schett G, Jäck HM, Voll RE, Meister S.

J Immunol. 2010 Nov 1;185(9):5637-47. doi: 10.4049/jimmunol.1001040. Epub 2010 Oct 4.

PMID:
20921528
[PubMed - indexed for MEDLINE]
Free Article
20.

Advantages and limits of ADAMTS13 testing in thrombotic thrombocytopenic purpura.

Franchini M, Mannucci PM.

Blood Transfus. 2008 Jul;6(3):127-35. Review. No abstract available.

PMID:
18705236
[PubMed - indexed for MEDLINE]
Free PMC Article
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk